Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
SI SIGA SIGA TECHNOLOGIES INC FY ended Feb 13, 2026 | $3.06 | $219.86M | $56.20M | $94.57M | $33.40M | $23.28M | 9.56x | 2.32x | 1.68x |
AM AMPH Amphastar Pharmaceuticals, Inc. FY ended Feb 20, 2026 | $22.01 | $936.26M | $1.24B | $719.89M | $207.48M | $98.09M | 10.84x | 1.30x | 5.17x |
CP CPRX CATALYST PHARMACEUTICALS, INC. FY ended Apr 27, 2026 | $31.49 | $3.85B | $3.27B | $588.99M | $321.85M | $214.33M | 18.74x | 6.54x | 10.15x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.76 | $3.61B | $13.79B | $6.22B | $1.29B | $187.00M | 19.11x | 0.58x | 10.69x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 7.23x | 4/6 | $1.64B | $31.99 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 6.59x | 6/6 | $4.90B | $95.53 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 6.31x | 6/6 | $331.78M | $6.47 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
SI SIGA SIGA TECHNOLOGIES INC FY ended Feb 13, 2026 | $3.06 | $219.86M | $56.20M | $94.57M | $33.40M | $23.28M | 9.56x | 2.32x | 1.68x |
AM AMPH Amphastar Pharmaceuticals, Inc. FY ended Feb 20, 2026 | $22.01 | $936.26M | $1.24B | $719.89M | $207.48M | $98.09M | 10.84x | 1.30x | 5.17x |
CP CPRX CATALYST PHARMACEUTICALS, INC. FY ended Apr 27, 2026 | $31.49 | $3.85B | $3.27B | $588.99M | $321.85M | $214.33M | 18.74x | 6.54x | 10.15x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.76 | $3.61B | $13.79B | $6.22B | $1.29B | $187.00M | 19.11x | 0.58x | 10.69x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 7.23x | 4/6 | $1.64B | $31.99 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 6.59x | 6/6 | $4.90B | $95.53 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 6.31x | 6/6 | $331.78M | $6.47 | Included in the active peer mix. |
